a phase ii study of docetaxel and epirubicin in advanced adult soft tissue sarcomas (sts)第二阶段研究紫杉醇和表柔比星在先进的成人软组织肉瘤(sts).pdfVIP

Sarcoma, December 2004, VOL. 8, NO. 4, 129–133 ORIGINAL ARTICLE A phase II study of docetaxel and epirubicin in advanced adult soft tissue sarcomas (STS) 1 2 HARALABOS P. KALOFONOS , CHARALABOS KOUROUSIS , MICHALIS V. KARAMOUZIS1 1 1 1 , GREGORIS ICONOMOU , EKATERINI TSIATA , FOTIS TZORZIDIS , PANAGIOTIS MEGAS1, ELIAS LAMBIRIS3 VASILIOS GEORGOULIAS2 1Division of Oncology, Department of Medicine University Hospital, Patras Medical School, Rion, Greece 2Department of Medical Oncology, School of Medicine, University General Hospital of Heraclion, Crete Greece 3Department of Orthopedics, University Hospital, Patras Medical School, Rion, Greece Abstract Purpose: The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS. Patients and Methods: Eighteen patients were treated with epirubicin 30 mg/m2 on days 1 to 3 and docetaxel 100 mg/m2 on day 1 every 3 weeks. Results: Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%) patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3–48 months) and the median time to disease progression was 4 months (range, 2–45 months). Grade 3 neutropenia occurred in 88% and neutropenic fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred. Discussion: Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with advanced STS. Introduction result in higher response rates than single-agent